Literature DB >> 23566490

The current national criteria for carotid artery stenting overestimate its efficacy in patients who are symptomatic and at high risk.

Shunsuke Yoshida1, Rodney P Bensley, Julia D Glaser, Christoph S Nabzdyk, Allen D Hamdan, Mark C Wyers, Elliot L Chaikof, Marc L Schermerhorn.   

Abstract

BACKGROUND: The Centers for Medicare and Medicaid Services (CMS) have established guidelines that outline patients who are considered "high risk" for complications after carotid endarterectomy (CEA) for which carotid artery stenting (CAS) may provide benefit. The validity of these high-risk criteria are yet unproven. In this study, we stratified patients who underwent CAS or CEA by CMS high-risk criteria and symptom status and examined their 30-day outcomes.
METHODS: A nonrandomized, retrospective cohort study was performed by chart review of all patients undergoing CEA or CAS from January 1, 2005, to December 31, 2010, at our institution. Demographic data and data pertaining to the presence or absence of high-risk factors were collected. Patients were stratified using symptom status and high-risk status as variables, and 30-day adverse events (stroke, death, myocardial infarction [MI]) were compared.
RESULTS: A total of 271 patients underwent CAS, with 30-day complication rates of stroke (3.0%), death (1.1%), MI (1.5%), stroke/death (3.7%), and stroke/death/MI (5.2%). A total of 830 patients underwent CEA with 30-day complication rates of stroke (2.0%), death (0.1%), MI (0.6%), stroke/death (1.9%), and stroke/death/MI (2.7%). Among symptomatic patients, physiologic high-risk status was associated with increased stroke/death (6 of 42 [14.3%] vs 2 of 74 [2.7%]; P < .01), and anatomic high-risk status was associated with a trend toward increased stroke/death (5 of 31 [16.1%] vs 0 of 20 [0.0%]; P = .14) in patients who underwent CAS vs CEA. Analysis of asymptomatic patients showed no differences between the two groups overall, except for a trend toward a higher rate of MI after CAS than after CEA (3 of 71 [4.2%] vs 0 of 108 [0.0%]; P = .06) in those who were physiologically at high risk. Among symptomatic patients who underwent CAS, patients with physiologic and anatomic high-risk factors had a higher rate of stroke/death than non-high-risk patients (6 of 42 [14.3%] vs 0 of 24 [0.0%] and 5 of 31 [16.1%] vs 0 of 24 [0.0%], respectively; both P ≤ .05).
CONCLUSIONS: Physiologic high-risk status was associated with increased stroke/death, whereas anatomic high-risk status showed a trend toward increased stroke/death in symptomatic patients undergoing CAS compared with non-high-risk patients undergoing CAS or physiologically high-risk patients undergoing CEA. Our results suggest that the current national criteria for CAS overestimate its efficacy in patients who are symptomatic and at high risk.
Copyright © 2013 Society for Vascular Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23566490      PMCID: PMC3696403          DOI: 10.1016/j.jvs.2012.12.075

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  21 in total

1.  Relaxing the rule of ten events per variable in logistic and Cox regression.

Authors:  Eric Vittinghoff; Charles E McCulloch
Journal:  Am J Epidemiol       Date:  2006-12-20       Impact factor: 4.897

2.  30 day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients: a randomised non-inferiority trial.

Authors:  P A Ringleb; J Allenberg; H Brückmann; H-H Eckstein; G Fraedrich; M Hartmann; M Hennerici; O Jansen; G Klein; A Kunze; P Marx; K Niederkorn; W Schmiedt; L Solymosi; R Stingele; H Zeumer; W Hacke
Journal:  Lancet       Date:  2006-10-07       Impact factor: 79.321

3.  Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis.

Authors:  Jean-Louis Mas; Gilles Chatellier; Bernard Beyssen; Alain Branchereau; Thierry Moulin; Jean-Pierre Becquemin; Vincent Larrue; Michel Lièvre; Didier Leys; Jean-François Bonneville; Jacques Watelet; Jean-Pierre Pruvo; Jean-François Albucher; Alain Viguier; Philippe Piquet; Pierre Garnier; Fausto Viader; Emmanuel Touzé; Maurice Giroud; Hassan Hosseini; Jean-Christophe Pillet; Pascal Favrole; Jean-Philippe Neau; Xavier Ducrocq
Journal:  N Engl J Med       Date:  2006-10-19       Impact factor: 91.245

4.  Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST)

Authors: 
Journal:  Lancet       Date:  1998-05-09       Impact factor: 79.321

5.  Safety of stenting and endarterectomy by symptomatic status in the Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST).

Authors:  Frank L Silver; Ariane Mackey; Wayne M Clark; William Brooks; Carlos H Timaran; David Chiu; Larry B Goldstein; James F Meschia; Robert D Ferguson; Wesley S Moore; George Howard; Thomas G Brott
Journal:  Stroke       Date:  2011-02-09       Impact factor: 7.914

6.  Protected carotid-artery stenting versus endarterectomy in high-risk patients.

Authors:  Jay S Yadav; Mark H Wholey; Richard E Kuntz; Pierre Fayad; Barry T Katzen; Gregory J Mishkel; Tanvir K Bajwa; Patrick Whitlow; Neil E Strickman; Michael R Jaff; Jeffrey J Popma; David B Snead; Donald E Cutlip; Brian G Firth; Kenneth Ouriel
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

7.  Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis.

Authors:  H J M Barnett; D W Taylor; R B Haynes; D L Sackett; S J Peerless; G G Ferguson; A J Fox; R N Rankin; V C Hachinski; D O Wiebers; M Eliasziw
Journal:  N Engl J Med       Date:  1991-08-15       Impact factor: 91.245

8.  Preoperative risk factors for carotid endarterectomy: defining the patient at high risk.

Authors:  Amy B Reed; Peter Gaccione; Michael Belkin; Magruder C Donaldson; John A Mannick; Anthony D Whittemore; Michael S Conte
Journal:  J Vasc Surg       Date:  2003-06       Impact factor: 4.268

9.  Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study.

Authors: 
Journal:  JAMA       Date:  1995-05-10       Impact factor: 56.272

10.  Defining the high-risk patient for carotid endarterectomy: an analysis of the prospective National Surgical Quality Improvement Program database.

Authors:  Michael C Stoner; William M Abbott; Daniel R Wong; Hong T Hua; Glenn M Lamuraglia; Chirstopher J Kwolek; Michael T Watkins; Arvind K Agnihotri; William G Henderson; Shukri Khuri; Richard P Cambria
Journal:  J Vasc Surg       Date:  2006-02       Impact factor: 4.268

View more
  5 in total

1.  Contemporary outcomes after carotid endarterectomy in high-risk anatomic and physiologic patients.

Authors:  Vaishnavi Rao; Patric Liang; Nicholas Swerdlow; Chun Li; Yoel Solomon; Mark Wyers; Marc Schermerhorn
Journal:  J Vasc Surg       Date:  2019-08-20       Impact factor: 4.268

Review 2.  Management of De Novo Carotid Stenosis and Postintervention Restenosis-Carotid Endarterectomy Versus Carotid Artery Stenting-a Review of Literature.

Authors:  Runqi Wangqin; Paul R Krafft; Keaton Piper; Jay Kumar; Kaya Xu; Maxim Mokin; Zeguang Ren
Journal:  Transl Stroke Res       Date:  2019-02-22       Impact factor: 6.829

3.  Carotid Endarterectomy: Current Concepts and Practice Patterns.

Authors:  Sibu P Saha; Subhajit Saha; Krishna S Vyas
Journal:  Int J Angiol       Date:  2015-08-14

Review 4.  Trials and Frontiers in Carotid Endarterectomy and Stenting.

Authors:  Douglas W Jones; Thomas G Brott; Marc L Schermerhorn
Journal:  Stroke       Date:  2018-06-04       Impact factor: 7.914

Review 5.  Clinical Outcomes of Second- versus First-Generation Carotid Stents: A Systematic Review and Meta-Analysis.

Authors:  Adam Mazurek; Krzysztof Malinowski; Kenneth Rosenfield; Laura Capoccia; Francesco Speziale; Gianmarco de Donato; Carlo Setacci; Christian Wissgott; Pasqualino Sirignano; Lukasz Tekieli; Andrey Karpenko; Waclaw Kuczmik; Eugenio Stabile; David Christopher Metzger; Max Amor; Adnan H Siddiqui; Antonio Micari; Piotr Pieniążek; Alberto Cremonesi; Joachim Schofer; Andrej Schmidt; Piotr Musialek
Journal:  J Clin Med       Date:  2022-08-17       Impact factor: 4.964

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.